Halozyme Therapeutics Inc (HALO) — Cash Flow Quality Index
Halozyme Therapeutics Inc (HALO) has a Cash Flow Quality Index of 1.02x as of September 2025. Operating cash flow of $178.60 Million exceeds net income of $175.22 Million, indicating high earnings quality where cash backs reported profits. Also explore Halozyme Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Halozyme Therapeutics Inc Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Halozyme Therapeutics Inc across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Halozyme Therapeutics Inc (HALO) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Halozyme Therapeutics Inc (2017–2024)
Year-by-year earnings quality comparison for Halozyme Therapeutics Inc. For live market cap and the full company financial profile, see HALO market cap.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.08x | $479.06 Million | $444.09 Million | ▼ -21.8% |
| 2023 | 1.38x | $388.57 Million | $281.59 Million | ▲ +16.2% |
| 2022 | 1.19x | $240.11 Million | $202.13 Million | ▲ +59.8% |
| 2021 | 0.74x | $299.44 Million | $402.71 Million | ▲ +73.1% |
| 2020 | 0.43x | $55.45 Million | $129.09 Million | ▼ -79.8% |
| 2017 | 2.13x | $134.05 Million | $62.97 Million | — |